{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:52:14Z","timestamp":1776387134014,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Taiho Pharma Asia Pacific Pte. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03077-4","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T05:07:26Z","timestamp":1736744846000},"page":"1222-1236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trifluridine\/Tipiracil (FTD\/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Ka-On","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Hoi-Lam","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland Ching-Yu","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikki","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-0305","authenticated-orcid":false,"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"3077_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11894-019-0703-8","volume":"21","author":"EF Onyoh","year":"2019","unstructured":"Onyoh EF, Hsu WF, Chang LC, Lee YC, Wu MS, Chiu HM. The rise of colorectal cancer in Asia: epidemiology, screening, and management. Curr Gastroenterol Rep. 2019;21:36.","journal-title":"Curr Gastroenterol Rep"},{"key":"3077_CR2","unstructured":"World Health Organization. Colorectal Cancer: Globocan. 2020. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/10_8_9-Colorectum-fact-sheet.pdf. Accessed 15 Feb 2022."},{"key":"3077_CR3","unstructured":"Hong Kong Cancer Registry. 10 most common cancers in Hong Kong in 2019. https:\/\/www3.ha.org.hk\/cancereg\/. Accessed 6 May\u00a02023."},{"key":"3077_CR4","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Colon and Rectum Cancer. https:\/\/seer.cancer.gov\/explorer\/application.html. Accessed 16 Mar 2022."},{"key":"3077_CR5","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3390\/cancers12113308","volume":"12","author":"E Osterman","year":"2020","unstructured":"Osterman E, Hammarstrom K, Imam I, Osterlund E, Sjoblom T, Glimelius B. Recurrence risk after radical colorectal cancer surgery-less than before, but how high is it? Cancers (Basel). 2020;12:3308.","journal-title":"Cancers (Basel)"},{"key":"3077_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","volume":"109","author":"DP Modest","year":"2019","unstructured":"Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer. 2019;109:70\u201383.","journal-title":"Eur J Cancer"},{"key":"3077_CR7","unstructured":"US Food and Drugs Administration. LONSURF (trifluridine and tipiracil) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/207981s008lbl.pdf. Accessed 15 February 2022."},{"key":"3077_CR8","unstructured":"Japan Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare. Lonsurf licensing. https:\/\/www.pmda.go.jp\/files\/000207987.pdf. Accessed 15 February 2022."},{"key":"3077_CR9","unstructured":"European Medicines Agency. Lonsurf summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lonsurf-epar-product-information_en.pdf. Accessed 15 February 2022."},{"key":"3077_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","volume":"41","author":"HJ Lenz","year":"2015","unstructured":"Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015;41:777\u201383.","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 1","key":"3077_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajco.13336","volume":"16","author":"T Price","year":"2020","unstructured":"Price T, Burge M, Chantrill L, et al. Trifluridine\/tipiracil: a practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Asia Pac J Clin Oncol. 2020;16(Suppl 1):3\u201312.","journal-title":"Asia Pac J Clin Oncol"},{"key":"3077_CR12","first-page":"630","volume":"14","author":"BA Weinberg","year":"2016","unstructured":"Weinberg BA, Marshall JL, Salem ME. Trifluridine\/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016;14:630\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3077_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase\u00a02 trial. Lancet Oncol. 2012;13:993\u20131001.","journal-title":"Lancet Oncol"},{"key":"3077_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"3077_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","volume":"90","author":"E Van Cutsem","year":"2018","unstructured":"Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase\u00a0III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63\u201372.","journal-title":"Eur J Cancer"},{"key":"3077_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36:350\u20138.","journal-title":"J Clin Oncol"},{"key":"3077_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1\u201342.","journal-title":"Int J Clin Oncol"},{"key":"3077_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"3077_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101558","volume":"8","author":"T Yoshino","year":"2023","unstructured":"Yoshino T, Cervantes A, Bando H, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023;8:101558.","journal-title":"ESMO Open"},{"key":"3077_CR20","doi-asserted-by":"publisher","first-page":"e240029","DOI":"10.6004\/jnccn.2024.0029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, et al. Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:e240029.","journal-title":"J Natl Compr Canc Netw"},{"key":"3077_CR21","doi-asserted-by":"crossref","unstructured":"Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367.","DOI":"10.1056\/NEJMoa2214963"},{"issue":"suppl 4","key":"3077_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.2017.35.4_suppl.775","volume":"35","author":"A Ohtsu","year":"2017","unstructured":"Ohtsu A, Yoshino T, Falcone A, et al. Onset of neutropenia as an indicator of treatment in the phase\u00a03 RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. J Clin Oncol. 2017;35(suppl 4):775.","journal-title":"J Clin Oncol"},{"key":"3077_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino T, Cleary JM, Van Cutsem E, et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020;31:88\u201395.","journal-title":"Ann Oncol"},{"key":"3077_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","volume":"16","author":"PM Kasi","year":"2016","unstructured":"Kasi PM, Kotani D, Cecchini M, et al. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer. 2016;16:467.","journal-title":"BMC Cancer"},{"key":"3077_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clcc.2016.07.005","volume":"16","author":"S Hamauchi","year":"2017","unstructured":"Hamauchi S, Yamazaki K, Masuishi T, et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer. 2017;16:51\u20137.","journal-title":"Clin Colorectal Cancer"},{"key":"3077_CR26","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","volume":"15","author":"PH O'Donnell","year":"2009","unstructured":"O\u2019Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15:4806\u201314.","journal-title":"Clin Cancer Res"},{"key":"3077_CR27","unstructured":"Hospital Authority. Hospital Authority Statistical Report 2020-2021. https:\/\/www3.ha.org.hk\/data\/HAStatistics\/DownloadReport\/8?isPreview=False. Accessed 23 Apr 2024."},{"key":"3077_CR28","unstructured":"The R Project. The R project for statistical computing. https:\/\/www.r-project.org\/. Accessed 7 February 2022."},{"key":"3077_CR29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2147\/OTT.S194605","volume":"12","author":"M Byrne","year":"2019","unstructured":"Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. Onco Targets Ther. 2019;12:2271\u20138.","journal-title":"Onco Targets Ther"},{"key":"3077_CR30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.clcc.2021.09.009","volume":"20","author":"C Stavraka","year":"2021","unstructured":"Stavraka C, Pouptsis A, Synowiec A, et al. Trifluridine\/tipiracil in metastatic colorectal cancer: a UK multicenter real-world analysis on efficacy, safety, predictive and prognostic factors. Clin Colorectal Cancer. 2021;20:342\u20139.","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"3077_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ijc.34603","volume":"153","author":"H Kr\u00f6ning","year":"2023","unstructured":"Kr\u00f6ning H, G\u00f6hler T, Decker T, et al. Effectiveness, safety and quality of life of trifluridine\/tipiracil in pretreated patients with metastatic colorectal cancer: real-world data from the noninterventional TACTIC study in Germany. Int J Cancer. 2023;153:1227\u201340.","journal-title":"Int J Cancer"},{"issue":"3","key":"3077_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000698","volume":"5","author":"JB Bachet","year":"2020","unstructured":"Bachet JB, Wyrwicz L, Price T, et al. Safety, efficacy and patient-reported outcomes with trifluridine\/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open. 2020;5:e000698.","journal-title":"ESMO Open"},{"issue":"5","key":"3077_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3747\/co.26.5107","volume":"26","author":"HH Samawi","year":"2019","unstructured":"Samawi HH, Brezden-Masley C, Afzal AR, Cheung WY, Dolley A. Real-world use of trifluridine\/tipiracil for patients with metastatic colorectal cancer in Canada. Curr Oncol. 2019;26:319\u201329.","journal-title":"Curr Oncol"},{"key":"3077_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000752","volume":"5","author":"J Tabernero","year":"2020","unstructured":"Tabernero J, Argiles G, Sobrero AF, et al. Effect of trifluridine\/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open. 2020;5:e000752.","journal-title":"ESMO Open"},{"key":"3077_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100531","volume":"31","author":"MJ Sousa","year":"2022","unstructured":"Sousa MJ, Gomes I, Pereira TC, et al. The effect of prognostic factors at baseline on the efficacy of trifluridine\/tipiracil in patients with metastatic colorectal cancer: a Portuguese exploratory analysis. Cancer Treat Res Commun. 2022;31:100531.","journal-title":"Cancer Treat Res Commun"},{"key":"3077_CR36","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.annonc.2020.04.421","volume":"31","author":"A Alchawaf","year":"2020","unstructured":"Alchawaf A, Dawod M, Al-Ani M, et al. P-339 real-world data (RWD) of the use of trifluridine\/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: the Greater Manchester experience. Ann Oncol. 2020;31:S200.","journal-title":"Ann Oncol"},{"key":"3077_CR37","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/annonc\/mdq248","volume":"21","author":"K Shitara","year":"2010","unstructured":"Shitara K, Matsuo K, Takahari D, et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 2010;21:2403\u20139.","journal-title":"Ann Oncol"},{"key":"3077_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12885-021-08323-4","volume":"21","author":"P Gargiulo","year":"2021","unstructured":"Gargiulo P, Arenare L, Gridelli C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer. 2021;21:549.","journal-title":"BMC Cancer"},{"key":"3077_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ygyno.2014.03.013","volume":"133","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the Gynecologic Oncology Group. Gynecol Oncol. 2014;133:439\u201345.","journal-title":"Gynecol Oncol"},{"key":"3077_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00280-015-2805-9","volume":"76","author":"F Yamashita","year":"2015","unstructured":"Yamashita F, Komoto I, Oka H, et al. Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. Cancer Chemother Pharmacol. 2015;76:325\u201333.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3077_CR41","doi-asserted-by":"publisher","first-page":"175883592093608","DOI":"10.1177\/1758835920936089","volume":"12","author":"G Martini","year":"2020","unstructured":"Martini G, Dienstmann R, Ros J, et al. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Ther Adv Med Oncol. 2020;12:1758835920936089.","journal-title":"Ther Adv Med Oncol"},{"key":"3077_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"KS Cheung","year":"2018","unstructured":"Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28\u201335.","journal-title":"Gut"},{"key":"3077_CR43","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers13092002","volume":"13","author":"JS Wong","year":"2021","unstructured":"Wong JS, Dong Y, Tang V, et al. The use of cabozantinib in advanced hepatocellular carcinoma in Hong Kong-a territory-wide cohort study. Cancers (Basel). 2021;13:2002.","journal-title":"Cancers (Basel)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03077-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:54:12Z","timestamp":1738407252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03077-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3077"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03077-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karen Hoi-Lam Li has received support for meeting attendance and travel from Taiho Pharma Asia Pacific Pte. Ltd. Ka-On Lam has received speaking honoraria from Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., GSK PLC, Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, and Taiho Pharma Asia Pacific Pte. Ltd. Ka-On Lam has also received meeting and travel support from Merck & Co. Inc. and Taiho Pharma Asia Pacific Pte. Ltd. and advisory board honoraria from Amgen Inc., Astellas Pharma Inc., and GSK PLC. Roland Ching-Yu Leung, Vikki Tang and Thomas Chung-Cheung Yau have no conflicts of interest to disclose. No payment or honoraria have been received by any author for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed for ethics, science and compliance with the Declaration of Helsinki, ICH GCP guidelines, local regulations, Hospital Authority and university policies. The protocol, encompassing the use of CDARS data from all participating centers, was approved by the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster before any data collection occurred (IRB reference number UW 19-460). The requirement for informed consent was waived owing to the anonymous nature of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}